Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 1 of 1 entries
View as:
Phase: N/A
Priority: Normal
Start: 10/01/21
End: 05/01/24
Due: 05/01/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer | NCT04975451 | Anqin Zhang | user2@example.com | None | 2021-10-01 | 2024-05-01 | 2025-05-01 | - | - | 2025-07-14 |